Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non- Dilutive FENG Application to Advance PC111 Through Human Proof of Concept [Accessibility Statement] Skip NavigationJERUSALEM, March 2, 2026 /PRNewswire/ -- [Scinai Immunotherapeutics Ltd.](Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., and the submission of a revised application under the European ...